OncoMatch/Clinical Trials/NCT06807437
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Is NCT06807437 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Lanreotide for pancreatic carcinoma.
Treatment: Lanreotide — This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Prior therapy
Cannot have received: somatostatin analogue
Cannot have received: radiation therapy
Cannot have received: peptide receptor radionuclide therapy
Lab requirements
Kidney function
creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula within 60 days prior to registration/randomization
Liver function
must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either AST > 190 U/L or ALT > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula within 60 days prior to registration/randomization; must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either AST > 190 U/L or ALT > 320 U/L) within 60 days prior to registration/randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis · Daphne, Alabama
- Thomas Hospital · Fairhope, Alabama
- Mobile Infirmary Medical Center · Mobile, Alabama
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland · Saraland, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify